MX2018005202A - Anticuerpos que serán reticulados con sema3a de humanos y ratones y sus usos. - Google Patents

Anticuerpos que serán reticulados con sema3a de humanos y ratones y sus usos.

Info

Publication number
MX2018005202A
MX2018005202A MX2018005202A MX2018005202A MX2018005202A MX 2018005202 A MX2018005202 A MX 2018005202A MX 2018005202 A MX2018005202 A MX 2018005202A MX 2018005202 A MX2018005202 A MX 2018005202A MX 2018005202 A MX2018005202 A MX 2018005202A
Authority
MX
Mexico
Prior art keywords
sema3a
antibody
present
cancer
linked
Prior art date
Application number
MX2018005202A
Other languages
English (en)
Inventor
Hyun Nam Do
Jae Shin Yong
Hyun Lee Jae
Original Assignee
Samsung Life Public Welfare Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Life Public Welfare Foundation filed Critical Samsung Life Public Welfare Foundation
Priority claimed from PCT/KR2016/012072 external-priority patent/WO2017074013A1/ko
Publication of MX2018005202A publication Critical patent/MX2018005202A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona un anticuerpo que tiene capacidad de reticulación contra Sema3A de humano y Sema3A de ratón. El anticuerpo de la presente invención se puede usar como fármacos de anticuerpos terapéuticos para inhibir Sema3A en diversos cánceres en los que la expresión de Sema3A es alta, tal como glioblastoma, cáncer de páncreas y cáncer de hígado. Desde Sema3A se considera que es un objetivo terapéutico de la retinopatía diabética, artritis autoinmune, dolor neuropático y la osteoporosis, el anticuerpo de la presente invención o un fragmento de unión a antígeno del mismo se pueden utilizar como un agente terapéutico para enfermedades asociadas además de un fármaco anti-cancerígeno. El anticuerpo de la presente invención inhibe el crecimiento de células de cáncer derivadas de diversos carcinomas través de la inhibición de la función Sema3A debido a la unión de alta anti-Sema3A, inhibe el movimiento de las células cancerosas a través de la inhibición de la fosforilación de ERK entre Sema3A inferiores sustancias de señalización, es muy eficaz en la prevención y el tratamiento del cáncer.
MX2018005202A 2015-10-27 2016-10-26 Anticuerpos que serán reticulados con sema3a de humanos y ratones y sus usos. MX2018005202A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150149272 2015-10-27
KR1020160123233A KR101854529B1 (ko) 2015-10-27 2016-09-26 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
PCT/KR2016/012072 WO2017074013A1 (ko) 2015-10-27 2016-10-26 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도

Publications (1)

Publication Number Publication Date
MX2018005202A true MX2018005202A (es) 2019-05-16

Family

ID=58742335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005202A MX2018005202A (es) 2015-10-27 2016-10-26 Anticuerpos que serán reticulados con sema3a de humanos y ratones y sus usos.

Country Status (6)

Country Link
US (1) US20180346567A1 (es)
EP (1) EP3385281A4 (es)
JP (2) JP6886474B2 (es)
KR (1) KR101854529B1 (es)
BR (1) BR112018008348A2 (es)
MX (1) MX2018005202A (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020267874A1 (en) 2019-05-09 2021-10-28 Boehringer Ingelheim International Gmbh Anti-Sema3A antibodies and their uses for treating eye or ocular diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007803A2 (en) * 2001-07-20 2003-01-30 Mount Sinai School Of Medicine Of New York University Methods for diagnosing and treating alzheimer's disease and parkinson's disease
US20120322085A1 (en) * 2009-11-05 2012-12-20 Osaka University Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
WO2011066284A1 (en) * 2009-11-25 2011-06-03 The University Of North Carolina At Chapel Hill Methods and compositions for the treatment of immune disorders
ES2728854T3 (es) * 2013-02-06 2019-10-29 Univ Yokohama City Anticuerpo anti-semaforina 3A y tratamiento de enfermedad de Alzheimer y enfermedades inmunitarias inflamatorias usando el mismo
US10139412B2 (en) * 2013-12-02 2018-11-27 The Fund for Medical Research, Development of Infrastructure and Health Services—Bnai Zion Medical Center Semaphorin 3A as a diagnostic marker for urothelial cancer

Also Published As

Publication number Publication date
JP2019500889A (ja) 2019-01-17
JP2020090528A (ja) 2020-06-11
EP3385281A1 (en) 2018-10-10
US20180346567A1 (en) 2018-12-06
KR20170051213A (ko) 2017-05-11
BR112018008348A2 (pt) 2018-10-30
KR101854529B1 (ko) 2018-05-04
EP3385281A4 (en) 2019-08-21
JP6886474B2 (ja) 2021-06-16

Similar Documents

Publication Publication Date Title
PH12018500642A1 (en) Anti-garp antibody
PH12018502046A1 (en) Methods for inhibiting angiogenesis in a subject in need thereof
PH12019501706A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
GEP20217328B (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
EA201790521A1 (ru) Направленная доставка лекарственных веществ, содержащих третичный амин
PH12017502270A1 (en) Combination therapy for the treatment of cancer
EA201992350A1 (ru) Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
BR112018067802A2 (pt) anticorpos anti-cd40 com atividade agonista melhorada
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
EA201791736A1 (ru) Комбинированная терапия для лечения рака
BR112022009631A2 (pt) Combinações de inibidores de dgk e antagonistas do ponto de checagem
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
PH12021550226A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
BR112016019176A2 (pt) anticorpos il-21
MX2017009246A (es) Farmaco de combinacion.
EA201990988A1 (ru) Антитела против chikv и пути их применения
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2018005202A (es) Anticuerpos que serán reticulados con sema3a de humanos y ratones y sus usos.
BR112019011370A2 (pt) terapia de combinação
EA202090485A1 (ru) Способы лечения рака путем ингибирования setd2